Tapewire

NYSE · USD

HAE

HAEMONETICS CORP

Export transactions ↓
Tapewire entity
3953
SEC CIK
0000313143
Parsed reports
416

Last 12 months

Inside the activity.

1 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202510
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 16, 2022 Filed May 18, 2022 20:34 UTC
DArecca JamesEVP, Chief Financial Officer
GrantNon-qualified Stock Option (Right to Buy) · Derivative 11,163 $0.00 Strike: $57.60 $0.00
Disclosure

SEC source: 0001127602-22-014966 · form4.xml · derivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,163

Underlying: Common Stock · 11,163 shares

Expires 2029-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 16, 2022 Filed May 18, 2022 20:34 UTC
DArecca JamesEVP, Chief Financial Officer
GrantCommon Stock 4,774 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-014966 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,676

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 16, 2022 Filed May 18, 2022 20:26 UTC
Simon, ChristopherDirector · President & CEO
GrantNon-qualified Stock Option (Right to Buy) · Derivative 60,891 $0.00 Strike: $57.60 $0.00
Disclosure

SEC source: 0001127602-22-014951 · form4.xml · derivative · entry 3

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,891

Underlying: Common Stock · 60,891 shares

Expires 2029-05-16

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 16, 2022 Filed May 18, 2022 20:26 UTC
Simon, ChristopherDirector · President & CEO
GrantCommon Stock 26,041 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-014951 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,368

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.

Read SEC document
May 16, 2022 Filed May 18, 2022 20:26 UTC
Simon, ChristopherDirector · President & CEO
SaleCommon Stock 832 $56.10 $46,675.20
Disclosure

SEC source: 0001127602-22-014951 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,327

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.

Read SEC document
May 02, 2022 Filed May 4, 2022 20:41 UTC
DArecca JamesEVP, Chief Financial Officer
GrantNon-qualified Stock Option (Right to Buy) · Derivative 13,828 $0.00 Strike: $50.83 $0.00
Disclosure

SEC source: 0001127602-22-013206 · form4.xml · derivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,828

Underlying: Common Stock · 13,828 shares

Expires 2029-05-02

F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 02, 2022 Filed May 4, 2022 20:41 UTC
DArecca JamesEVP, Chief Financial Officer
GrantCommon Stock 5,902 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-013206 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,902

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
April 18, 2022 Filed Apr 19, 2022 20:19 UTC
Lingamneni AnilaEVP, Chief Technology Officer
SaleCommon Stock 189 $56.55 $10,687.95
Disclosure

SEC source: 0001127602-22-012143 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,013

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
October 25, 2021 Filed Oct 27, 2021 20:58 UTC
Strong Stewart WPresident, Global Hospital
SaleCommon Stock 75 $71.93 $5,394.75
Disclosure

SEC source: 0001127602-21-027704 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,717

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
October 25, 2021 Filed Oct 27, 2021 20:49 UTC
Basil Michelle LEVP and General Counsel
SaleCommon Stock 120 $71.93 $8,631.60
Disclosure

SEC source: 0001127602-21-027702 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,290

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
September 17, 2021 Filed Sep 22, 2021 01:20 UTC
Miller Laurie A.SVP, Human Resources
GrantCommon Stock 2,848 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-036959 · doc4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,081

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Equity Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Equity Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This includes unvested RSUs previously reported.

Read SEC document
September 07, 2021 Filed Sep 9, 2021 20:56 UTC
Llorens JosepEVP, Global Manufacturing
SaleCommon Stock 100 $64.61 $6,461.00
Disclosure

SEC source: 0000899243-21-035451 · doc4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,520

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
August 23, 2021 Filed Aug 25, 2021 20:15 UTC
Burke William P. Mr.EVP, Chief Financial Officer
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 11,435 $0.00 Strike: $41.64 $0.00
Disclosure

SEC source: 0000899243-21-034143 · doc4.xml · derivative · entry 5

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,435 shares

Expires 2024-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

Read SEC document
August 23, 2021 Filed Aug 25, 2021 20:15 UTC
Burke William P. Mr.EVP, Chief Financial Officer
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 11,232 $0.00 Strike: $34.21 $0.00
Disclosure

SEC source: 0000899243-21-034143 · doc4.xml · derivative · entry 4

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,232 shares

Expires 2023-10-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

Read SEC document
August 23, 2021 Filed Aug 25, 2021 20:15 UTC
Burke William P. Mr.EVP, Chief Financial Officer
SaleCommon Stock 22,667 $60.51 $1,371,580.17
Disclosure

SEC source: 0000899243-21-034143 · doc4.xml · nonDerivative · entry 3

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,291

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · price: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
August 23, 2021 Filed Aug 25, 2021 20:15 UTC
Burke William P. Mr.EVP, Chief Financial Officer
Exercise / conversionCommon Stock 11,435 $41.64 $476,153.40
Disclosure

SEC source: 0000899243-21-034143 · doc4.xml · nonDerivative · entry 2

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,958

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
August 23, 2021 Filed Aug 25, 2021 20:15 UTC
Burke William P. Mr.EVP, Chief Financial Officer
Exercise / conversionCommon Stock 11,232 $34.21 $384,246.72
Disclosure

SEC source: 0000899243-21-034143 · doc4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,523

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 23:30 UTC GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023397 · form4.xml · nonDerivative · entry 1

Pomeroy Claire · CIK 0001603648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,016

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 23:25 UTC
KROLL MARK WDirector
GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023396 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,517

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 23:22 UTC GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023395 · form4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,400

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: Includes 8,568 shares previously held by a grantor retained annuity trust, of which Mr. Dockendorff is the sole trustee, pursuant to an exempt transfer by such trust.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 23:18 UTC GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023393 · form4.xml · nonDerivative · entry 1

COYLE MICHAEL J · CIK 0001233311 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,538

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 23:14 UTC GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023391 · form4.xml · nonDerivative · entry 1

BURZIK CATHERINE M · CIK 0001261141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,815

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 23:10 UTC GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023389 · form4.xml · nonDerivative · entry 1

ABERNATHY ROBERT E · CIK 0001222888 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,125

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 22:54 UTC GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023386 · form4.xml · nonDerivative · entry 1

Johnson Lloyd Emerson · CIK 0001708823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,077

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
August 06, 2021 Filed Aug 9, 2021 22:59 UTC
Zane Ellen MDirector
GrantCommon Stock 3,077 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-023387 · form4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,517

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Read SEC document
July 01, 2021 Filed Jul 6, 2021 20:21 UTC
Burke William P. Mr.EVP, Chief Financial Officer
SaleCommon Stock 4,293 $66.60 $285,913.80
Disclosure

SEC source: 0001127602-21-021568 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,291

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:39 UTC
Goldstein DanVP, Corporate Controller
SaleCommon Stock 39 $59.87 $2,334.93
Disclosure

SEC source: 0001127602-21-020056 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,054

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:35 UTC
Basil Michelle LEVP and General Counsel
SaleCommon Stock 195 $59.87 $11,674.65
Disclosure

SEC source: 0001127602-21-020055 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,410

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:31 UTC
Burke William P. Mr.EVP, Chief Financial Officer
SaleCommon Stock 190 $59.87 $11,375.30
Disclosure

SEC source: 0001127602-21-020050 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,584

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:29 UTC
Simon, ChristopherDirector · President & CEO
SaleCommon Stock 1,200 $59.87 $71,844.00
Disclosure

SEC source: 0001127602-21-020048 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,806

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:35 UTC
Goldstein DanVP, Corporate Controller
SaleCommon Stock 81 $55.09 $4,462.29
Disclosure

SEC source: 0001127602-21-019529 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,093

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:33 UTC
Scanlan JacquelineSVP, Global Human Resources
SaleCommon Stock 195 $55.09 $10,742.55
Disclosure

SEC source: 0001127602-21-019526 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,216

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:31 UTC
Basil Michelle LEVP and General Counsel
SaleCommon Stock 442 $55.09 $24,349.78
Disclosure

SEC source: 0001127602-21-019523 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,605

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:29 UTC
Burke William P. Mr.EVP, Chief Financial Officer
SaleCommon Stock 411 $55.09 $22,641.99
Disclosure

SEC source: 0001127602-21-019522 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,774

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:27 UTC
Simon, ChristopherDirector · President & CEO
SaleCommon Stock 2,715 $55.09 $149,569.35
Disclosure

SEC source: 0001127602-21-019521 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,006

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:42 UTC
Goldstein DanVP, Corporate Controller
GrantCommon Stock 1,753 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-018998 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,174

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 26, 2021 Filed May 28, 2021 20:09 UTC
KROLL MARK WDirector
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 10,353 $0.00 Strike: $35.50 $0.00
Disclosure

SEC source: 0001127602-21-018310 · form4.xml · derivative · entry 3

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,353 shares

Expires 2021-07-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option vests 100% on the first anniversary of the date of grant.

Read SEC document
May 26, 2021 Filed May 28, 2021 20:09 UTC
KROLL MARK WDirector
SaleCommon Stock 11,813 $55.10 $650,896.30
Disclosure

SEC source: 0001127602-21-018310 · form4.xml · nonDerivative · entry 2

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,440

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 26, 2021 Filed May 28, 2021 20:09 UTC
KROLL MARK WDirector
Exercise / conversionCommon Stock 10,353 $35.50 $367,557.38
Disclosure

SEC source: 0001127602-21-018310 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,253

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 19, 2021 Filed May 20, 2021 22:08 UTC
Goldstein DanVP, Corporate Controller
SaleCommon Stock 42 $55.19 $2,317.98
Disclosure

SEC source: 0001127602-21-017683 · form4.xml · nonDerivative · entry 2

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,421

F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 19, 2021 Filed May 20, 2021 22:07 UTC
Lingamneni AnilaEVP, Chief Technology Officer
SaleCommon Stock 92 $55.19 $5,077.48
Disclosure

SEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 3

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,202

F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

Read SEC document
May 19, 2021 Filed May 20, 2021 22:05 UTC
Llorens JosepSVP, Global Manufacturing
SaleCommon Stock 125 $55.19 $6,898.75
Disclosure

SEC source: 0001127602-21-017681 · form4.xml · nonDerivative · entry 3

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,620

F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 19, 2021 Filed May 20, 2021 22:02 UTC
Basil Michelle LEVP and General Counsel
SaleCommon Stock 220 $55.19 $12,141.80
Disclosure

SEC source: 0001127602-21-017680 · form4.xml · nonDerivative · entry 3

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,047

F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 19, 2021 Filed May 20, 2021 21:58 UTC
Burke William P. Mr.EVP, Chief Financial Officer
SaleCommon Stock 238 $55.19 $13,135.22
Disclosure

SEC source: 0001127602-21-017677 · form4.xml · nonDerivative · entry 3

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,185

F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 19, 2021 Filed May 20, 2021 21:55 UTC
Simon, ChristopherDirector · President & CEO
SaleCommon Stock 1,024 $55.19 $56,514.56
Disclosure

SEC source: 0001127602-21-017675 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,721

F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 19, 2021 Filed May 21, 2021 10:26 UTC
Scanlan JacquelineSVP, Global Human Resources
SaleCommon Stock 112 $55.19 $6,181.28
Disclosure

SEC source: 0001127602-21-017698 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,411

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 18, 2021 Filed May 20, 2021 22:08 UTC
Goldstein DanVP, Corporate Controller
GrantNon-qualified Stock Option (Right to Buy) · Derivative 2,690 $0.00 Strike: $56.57 $0.00
Disclosure

SEC source: 0001127602-21-017683 · form4.xml · derivative · entry 3

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,690

Underlying: Common Stock · 2,690 shares

Expires 2028-05-18

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 18, 2021 Filed May 20, 2021 22:08 UTC
Goldstein DanVP, Corporate Controller
GrantCommon Stock 994 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-017683 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,463

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 18, 2021 Filed May 20, 2021 22:07 UTC
Lingamneni AnilaEVP, Chief Technology Officer
GrantNon-qualified Stock Option (Right to Buy) · Derivative 9,564 $0.00 Strike: $56.57 $0.00
Disclosure

SEC source: 0001127602-21-017682 · form4.xml · derivative · entry 4

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,564

Underlying: Common Stock · 9,564 shares

Expires 2028-05-18

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 18, 2021 Filed May 20, 2021 22:07 UTC
Lingamneni AnilaEVP, Chief Technology Officer
GrantCommon Stock 7,070 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,294

F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.